Next generation anticoagulants: a spotlight on the potential role of activated factors XII and XI.
作者信息
Philippou Helen, Stavrou Evi X
机构信息
Leeds Institute of Cardiovascular & Metabolic Medicine, University of Leeds, Leeds, West Yorkshire, UK.
Department of Medicine, Hematology and Oncology Division, CWRU School of Medicine, Cleveland, OH, USA.
出版信息
Expert Rev Hematol. 2023 Jul-Dec;16(10):711-714. doi: 10.1080/17474086.2023.2245973. Epub 2023 Aug 10.
Abstract
摘要
相似文献
1
Next generation anticoagulants: a spotlight on the potential role of activated factors XII and XI.新一代抗凝剂：聚焦活化因子 XII 和 XI 的潜在作用。
Expert Rev Hematol. 2023 Jul-Dec;16(10):711-714. doi: 10.1080/17474086.2023.2245973. Epub 2023 Aug 10.
2
Factor XI and factor XII as targets for new anticoagulants.作为新型抗凝剂靶点的凝血因子XI和凝血因子XII。
Thromb Res. 2016 May;141 Suppl 2:S40-5. doi: 10.1016/S0049-3848(16)30363-2.
3
Factor XI activation in a revised model of blood coagulation.凝血修正模型中的因子XI激活
Science. 1991 Aug 23;253(5022):909-12. doi: 10.1126/science.1652157.
4
Factor XII promotes blood coagulation independent of factor XI in the presence of long-chain polyphosphates.在长链多聚磷酸盐存在的情况下，因子 XII 可促进血液凝结，而无需因子 XI 的参与。
J Thromb Haemost. 2013 Jul;11(7):1341-52. doi: 10.1111/jth.12295.
5
Inhibiting the intrinsic pathway of coagulation with a factor XII-targeting RNA aptamer.用一种靶向因子 XII 的 RNA 适体抑制凝血的内源性途径。
J Thromb Haemost. 2013 Jul;11(7):1364-73. doi: 10.1111/jth.12302.
6
Factor XI and XII as antithrombotic targets.因子 XI 和因子 XII 作为抗血栓靶点。
Curr Opin Hematol. 2011 Sep;18(5):349-55. doi: 10.1097/MOH.0b013e3283497e61.
7
Thrombin activates factor XI on activated platelets in the absence of factor XII.在缺乏因子 XII 的情况下，凝血酶可激活活化血小板上的因子 XI。
Arterioscler Thromb Vasc Biol. 1999 Jan;19(1):170-7. doi: 10.1161/01.atv.19.1.170.
8
Annexin A4 inhibits sulfatide-induced activation of coagulation factor XII.膜联蛋白A4抑制硫苷脂诱导的凝血因子XII激活。
J Thromb Haemost. 2020 Jun;18(6):1357-1369. doi: 10.1111/jth.14789. Epub 2020 May 6.
9
Triazol-1-yl Benzamides Promote Anticoagulant Activity Inhibition of Factor XIIa.三唑基苯甲酰胺促进抗凝活性 抑制因子 XIIa。
Cardiovasc Hematol Agents Med Chem. 2023;21(2):108-119. doi: 10.2174/1871525721666221031141323.
10
Factor XI as a Target for New Anticoagulants.因子 XI 作为新型抗凝剂的靶点。
Hamostaseologie. 2021 Apr;41(2):104-110. doi: 10.1055/a-1384-3715. Epub 2021 Apr 15.
本文引用的文献
1
Plasma Kallikrein as a Forgotten Clotting Factor.血浆激肽释放酶：被遗忘的凝血因子
Semin Thromb Hemost. 2024 Oct;50(7):953-961. doi: 10.1055/s-0043-57034. Epub 2023 Apr 18.
2
Glycated albumin modulates the contact system with implications for the kallikrein-kinin and intrinsic coagulation systems.糖化白蛋白调节接触系统，影响激肽释放酶-激肽系统和内在凝血系统。
J Thromb Haemost. 2023 Apr;21(4):814-827. doi: 10.1016/j.jtha.2022.12.015. Epub 2022 Dec 27.
3
Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial.急性非心源性缺血性脑卒中后用 asundexian 抑制因子 XIa（PACIFIC-Stroke）：一项国际、随机、双盲、安慰剂对照、2b 期试验。
Lancet. 2022 Sep 24;400(10357):997-1007. doi: 10.1016/S0140-6736(22)01588-4. Epub 2022 Sep 2.
4
Rationale and design of the AXIOMATIC-SSP phase II trial: Antithrombotic treatment with factor XIa inhibition to Optimize Management of Acute Thromboembolic events for Secondary Stroke Prevention.AXIOMATIC-SSP 二期试验的原理和设计：用因子 XIa 抑制进行抗血栓治疗，以优化急性血栓栓塞事件的管理，预防二次卒中。
J Stroke Cerebrovasc Dis. 2022 Oct;31(10):106742. doi: 10.1016/j.jstrokecerebrovasdis.2022.106742. Epub 2022 Aug 27.
5
A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction.一项多中心、2期、随机、安慰剂对照、双盲、平行组、剂量探索性试验，旨在研究口服凝血因子XIa抑制剂阿孙德西安预防急性心肌梗死后不良心血管事件的效果。
Circulation. 2022 Oct 18;146(16):1196-1206. doi: 10.1161/CIRCULATIONAHA.122.061612. Epub 2022 Aug 27.
6
Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study.口服因子 XIa 抑制剂 asundexian 与房颤患者的阿哌沙班（PACIFIC-AF）相比的安全性：一项多中心、随机、双盲、双模拟、剂量发现的 2 期研究。
Lancet. 2022 Apr 9;399(10333):1383-1390. doi: 10.1016/S0140-6736(22)00456-1. Epub 2022 Apr 3.
7
Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial.抗活化因子 XII 单克隆抗体 garadacimab 预防性治疗 C1 酯酶抑制剂缺乏遗传性血管性水肿患者的随机、双盲、安慰剂对照、2 期临床试验。
Lancet. 2022 Mar 5;399(10328):945-955. doi: 10.1016/S0140-6736(21)02225-X. Epub 2022 Feb 24.
8
Milvexian for the Prevention of Venous Thromboembolism.密尔沃基用于预防静脉血栓栓塞。
N Engl J Med. 2021 Dec 2;385(23):2161-2172. doi: 10.1056/NEJMoa2113194. Epub 2021 Nov 15.
9
Abelacimab for Prevention of Venous Thromboembolism.Abelacimab 用于预防静脉血栓栓塞。
N Engl J Med. 2021 Aug 12;385(7):609-617. doi: 10.1056/NEJMoa2105872. Epub 2021 Jul 19.
10
The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial.无肝素血液透析中接触激活抑制剂 AB023：一项随机 2 期临床试验结果。
Blood. 2021 Dec 2;138(22):2173-2184. doi: 10.1182/blood.2021011725.
Zotero 插件